Canopy Growth (CGC) Change in Accured Expenses (2019 - 2025)
Canopy Growth (CGC) reported Change in Accured Expenses of -$1.6 million for Q4 2025, down 143.64% on a YoY basis from $3.6 million in Q4 2024, and down 141.74% sequentially from $3.7 million in Q2 2025.
Canopy Growth (CGC) Change in Accured Expenses (2019 - 2025) Analysis & Trends
Canopy Growth (CGC) has 7 years of Change in Accured Expenses data on file, last reported at -$1.6 million in Q4 2025.
- For the quarter ending Q4 2025, Change in Accured Expenses fell 143.64% year-over-year to -$1.6 million; the trailing twelve-month figure through Dec 2025 stood at -$6.0 million (up 6.19% YoY), and the FY2026 full-year result was -$3.2 million, up 70.58% from the prior year.
- Change in Accured Expenses slipped to -$1.6 million in Q4 2025, from $3.7 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $10.7 million in Q3 2021 to a low of -$27.4 million in Q4 2021.
- A 5-year average of -$3.2 million and a median of -$2.9 million in 2022 frame the typical range for Change in Accured Expenses.
- Across the five-year window, Change in Accured Expenses jumped 983.78% in 2021 and tumbled 453.49% in 2022, its largest moves.
- Tracing CGC's Change in Accured Expenses over 5 years: stood at -$27.4 million in 2021, then jumped by 84.85% to -$4.2 million in 2022, then soared by 346.37% to $10.2 million in 2023, then slumped by 65.02% to $3.6 million in 2024, then tumbled by 143.64% to -$1.6 million in 2025.
- Business Quant data shows CGC's Change in Accured Expenses at -$1.6 million in Q4 2025, $3.7 million in Q2 2025, and $3.6 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.97 Bn | 87.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.95 Bn | 32.21 Bn | 1.97 Bn | -144.00 Mn |
| 3 | Zoetis | 32.26 Bn | 30.32 Bn | 1.62 Bn | -234.00 Mn |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.15 Bn | 21.00 Bn | 648.10 Mn | -12.70 Mn |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - | - |
| 7 | Viatris | 20.27 Bn | 18.46 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.86 Bn | 16.55 Bn | 800.70 Mn | -14.30 Mn |
| 9 | Elanco Animal Health | 12.66 Bn | 12.23 Bn | 785.00 Mn | - |
| 10 | Canopy Growth | 269.64 Mn | 3.71 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.56 Mn |
| Dec 31, 2025 | -1.56 Mn |
| Jun 30, 2025 | 3.74 Mn |
| Jun 30, 2025 | 3.74 Mn |
| Dec 31, 2024 | 3.58 Mn |
| Dec 31, 2024 | 3.58 Mn |
| Sep 30, 2024 | -11.79 Mn |
| Sep 30, 2024 | -11.79 Mn |
| Jun 30, 2024 | -4.32 Mn |
| Jun 30, 2024 | -4.32 Mn |
| Mar 31, 2024 | 6.10 Mn |
| Mar 31, 2024 | 6.10 Mn |
| Dec 31, 2023 | 10.23 Mn |
| Dec 31, 2023 | 10.23 Mn |
| Sep 30, 2023 | 3.71 Mn |
| Sep 30, 2023 | 3.71 Mn |
| Jun 30, 2023 | -13.41 Mn |
| Jun 30, 2023 | -13.41 Mn |
| Mar 31, 2023 | -6.77 Mn |
| Mar 31, 2023 | -6.77 Mn |